Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Fin
Go back to Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Fin| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 1.07 +0.05 (4.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.02 | 52 Week High | $13.20 | |||
| Open | $1.05 | 52 Week Low | $7.00 | |||
| Day High | $1.08 | P/E | N/A | |||
| Day Low | $1.00 | EPS | $0.00 | |||
| Volume | 22,933,787 | |||||
| Mitsubishi Chemical Holdings Corp Unsponsored ADR (AMEX: MTLHY) | Delayed: 34.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.70 | 52 Week High | $34.07 | |||
| Open | $34.70 | 52 Week Low | $21.84 | |||
| Day High | $34.70 | P/E | N/A | |||
| Day Low | $34.70 | EPS | $0.00 | |||
| Volume | 8 | |||||
| Mitsubishi Tanabe Pharma Corporation Sponsored ADR (AMEX: MTZPY) | Delayed: 18.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.60 | 52 Week High | $21.90 | |||
| Open | $0.13 | 52 Week Low | $15.98 | |||
| Day High | $18.60 | P/E | N/A | |||
| Day Low | $18.60 | EPS | $0.00 | |||
| Volume | 5,773 | |||||
